A pilot study of operational tolerance with a regulatory T‐cell‐based cell therapy in living donor liver transplantation

Abstract

Potent immunosuppressive drugs have significantly improved early patient survival after liver transplantation (LT). However, long-term results remain unsatisfactory because of adverse events that are largely associated with lifelong immunosuppression. To solve this problem, different strategies have been undertaken to induce operational tolerance, for example, maintenance of normal graft function and histology without immunosuppressive therapy, but have achieved limited success. In this pilot study, we aimed to induce tolerance using a novel regulatory T-cell-based cell therapy in living donor LT. Adoptive transfer of an ex vivo-generated regulatory T-cell-enriched cell product was conducted in 10 consecutive adult patients early post-LT. Cells were generated using a 2-week coculture of recipient lymphocytes with irradiated donor cells in the presence of anti-CD80/86 monoclonal antibodies. Immunosuppressive agents were tapered from 6 months, reduced every 3 months, and completely discontinued by 18 months. After the culture, the generated cells displayed cell-number-dependent donor-specific inhibition in the mixed lymphocyte reaction. Infusion of these cells caused no significant adverse events. Currently, all patients are well with normal graft function and histology. Seven patients have completed successful weaning and cessation of immunosuppressive agents. At present, they have been drug free for 16-33 months; 4 patients have been drug free for more than 24 months. The other 3 recipients with autoimmune liver diseases developed mild rejection during weaning and then resumed conventional low-dose immunotherapy. Conclusions: A cell therapy using an ex vivo-generated regulatory T-cell-enriched cell product is safe and effective for drug minimization and operational tolerance induction in living donor liver recipients with nonimmunological liver diseases. (HEPATOLOGY 2016;64:632-643) SEE EDITORIAL ON PAGE 347 E arly results after liver transplantation (LT) have been greatly improved by the evolution of potent antirejection agents. However, unfortunately, late outcomes remain unsatisfactory because of immunological and nonimmunological complications that are largely associated with lifelong immunosuppression (IS). They are infection, de novo malignancy, chronic rejection, and kidney, cardiovascular, and

Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I–II, open-label, clinical study

“…Tregs have been proposed to be key in strategies aiming for tolerance and immunomodulation after SOT [35]. In a recent paper, Todo et al demonstrated that a single Treg injection might promote operational tolerance after living-related LT [36]. Recently, it has been demonstrated both in vitro and in vivo that MSCs could promote Treg expansion by their effects on immature dendritic cells [37].…”

A New Immunotherapy Using Regulatory T-Cells for High-Risk Corneal Transplantation

“…Amazingly, Juntendo University, Tokyo, Japan and Hokkaido University, Hokkaido, Japan has succeeded in breaking away from immunosuppressive agents for human liver transplantation using ex vivo-generated regulatory T-cell-enriched cells 34) . After liver transplantations, 10 adult patients were given a novel regulatory T-cell-based cell therapy and have been drug free for 16-33 months since.…”

Restoring Regulatory T Cells in Type 1 Diabetes

“…In this regard promising results have been observed using tolerogenic islet antigens to inactivate effector T cells in animal models [124]. In Treg cell therapy, antigen specific Tregs produced by selective expansion in vitro has already been tested in liver transplantation and Crohn's disease [125,126]. The low frequency of islet antigen specific Tregs and the propensity of Tregs to destabilize after repeated in vitro stimulation makes selective expansion of islet antigen specific Tregs challenging.…”